通脉糖眼明胶囊对单纯型糖尿病视网膜病变患者VEGF水平的影响

目的:观察通脉糖眼明胶囊对单纯型糖尿病视网膜病变(diabetic retinopathy,DR)患者血管内皮生长因子(vascular endothelial growth factor,VEGF)水平的影响,探讨通脉糖眼明胶囊治疗糖尿病视网膜病变的可能机制。方法:DR患者68例随机分为通脉糖眼明胶囊治疗组36例,对照组32例,同时收集同年龄健康者30例为正常组,治疗组予通脉糖眼明胶囊治疗,比较治疗前后3组VEGF水平的变化。结果:DR患者VEGF水平显著升高,与正常组比较,差异有显著性意义(P<0.01);治疗8周后VEGF水平均下降,与治疗前相比差异有显著性意义(P<0.01);通脉糖眼明胶囊治疗组VEGF水平(116.50±22.34)下降尤为显著,与对照组(136.4±24.6)相比,差异有显著性意义(P<0.01)。结论:通脉糖眼明胶囊能有效降低DR患者VEGF水平,从而缓解DR病变进程。

Effect of Tongmai Tangyanming Capsule on Levels of Vascular EndothelialGrowth Factor in Patients with Non-proliferative Diabetic Retinopathy

Objective: To observe the effects and possible mechanism of Tongmai Tangyanming capsule on the levels of vascular endothelial growth factor(VEGF) in patients with non-proliferative diabetic retinopathy(DR). Method: Sixty-eight DR patients were randomly divided into 36 of tongmai tangyanming capsule treatment group and 32 of control group.30 of normal subject as normal group.The levels of VEGF were measured in three group pre and post treatment. Result: Serum levels of VEGF in DR group were significantly higher than those of the normal group (P<0.01).after 8 weeks treatment, when comparing with that before treatment, the levels of VEGF were decreased(P<0.01); Compared with control group, the levels of VEGF in the treated group decreased significantly(P<0.01). Conclusion: Tongmai tangyanming capsule can effectively decrease the levels of VEGF in DR patients, so that partly suppresses the development of diabetic retinopathy.